Co-Authors
This is a "connection" page, showing publications co-authored by Agostino Riva and Dario Cattaneo.
Connection Strength
1.476
-
Clinical Features and Outcomes of Patients With Human Immunodeficiency Virus With COVID-19. Clin Infect Dis. 2020 11 19; 71(16):2276-2278.
Score: 0.229
-
Does lopinavir really inhibit SARS-CoV-2? Pharmacol Res. 2020 08; 158:104898.
Score: 0.220
-
Darunavir does not prevent SARS-CoV-2 infection in HIV patients. Pharmacol Res. 2020 07; 157:104826.
Score: 0.219
-
Effects of ritonavir and cobicistat on dolutegravir exposure: when the booster can make the difference. J Antimicrob Chemother. 2017 06 01; 72(6):1842-1844.
Score: 0.180
-
Pharmacogenetics-based optimisation of atazanavir treatment: potential role of new genetic predictors. Drug Metab Pers Ther. 2017 05 24; 32(2):115-117.
Score: 0.179
-
The impact of gastrectomy on the pharmacokinetics of atazanavir and tenofovir. Eur J Clin Pharmacol. 2017 Jun; 73(6):789-790.
Score: 0.177
-
Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect? Antivir Ther. 2017; 22(4):353-356.
Score: 0.174
-
Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy. BMC Infect Dis. 2018 Nov 12; 18(1):556.
Score: 0.050
-
Clinical and genetic determinants of nevirapine plasma trough concentration. SAGE Open Med. 2018; 6:2050312118780861.
Score: 0.048